Einloggen

Thematische Bibliographien / 914.445 95

Inhaltsverzeichnis

Zeitschriftenartikel

Auswahl der wissenschaftlichen Literatur zum Thema „914.445 95“

Autor: Grafiati

Veröffentlicht am 18. Mai 2024

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "914.445 95" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Zeitschriftenartikel zum Thema "914.445 95"

1

Bowe, Benjamin, Yan Xie, Tingting Li, Yan Yan, Hong Xian, and Ziyad Al-Aly. "Estimates of the 2016 global burden of kidney disease attributable to ambient fine particulate matter air pollution." BMJ Open 9, no. 5 (2019): e022450. http://dx.doi.org/10.1136/bmjopen-2018-022450.

Der volle Inhalt der Quelle

Annotation:

ObjectiveTo quantitate the 2016 global and national burden of chronic kidney disease (CKD) attributable to ambient fine particulate matter air pollution ≤ 2.5 μm in aerodynamic diameter (PM2.5).DesignWe used the Global Burden of Disease (GBD) study data and methodologies to estimate the 2016 burden of CKD attributable to PM2.5in 194 countries and territories. Population-weighted PM2.5levels and incident rates of CKD for each country were curated from the GBD study publicly available data sources.SettingGBD global and national data on PM2.5and CKD.Participants194 countries and territories.Main

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Kotapati, Sravanthi, Insija Ilyas Selene, Madeeha Shafqat, et al. "Efficacy and Toxicity of Lenalidomide for Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis." Blood 134, Supplement_1 (2019): 5488. http://dx.doi.org/10.1182/blood-2019-129733.

Der volle Inhalt der Quelle

Annotation:

Background: During last decade, several therapeutic options have emerged for newly diagnosed (ND) or relapsed / refractory (RR) patients with chronic lymphocytic leukemia (CLL). Lenalidomide (Lena) has immunomodulatory, anti-angiogenic and antitumor activity. Lena is showing antitumor activity against CLL with durable responses.The main aim of our analysis is to study the published literature on the efficacy and safety of Lena based regimens in patients with ND and RR CLL. Methods: We performed the literature search (10/5/2019) using following databases (PubMed, Embase, Cochrane Library, Web o

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Christensen, S. "Removal of haem from lipids extracted from intact erythrocytes with particular reference to polyphosphoinositides." Biochemical Journal 233, no. 3 (1986): 921–24. http://dx.doi.org/10.1042/bj2330921.

Der volle Inhalt der Quelle

Annotation:

With the use of a modified acid version of a current lipid-extraction technique [Bligh & Dyer (1959) Can. J. Biochem. Physiol. 37, 911-917], 92% of phosphatidylinositol 4,5-bisphosphate obtained by means of three sequential extractions from intact human erythrocytes was obtained during the first one. Some 95% of the haem co-extracted with the lipids could then be removed, with a maximal loss of polyphosphoinositides of less than 3%. About 58 nmol of phosphatidylinositol 4,5-bisphosphate was found per ml of erythrocytes.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Bradbury, Charlotte A., Zoe Craig, Gordon Cook, et al. "Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials." Blood 136, no. 9 (2020): 1091–104. http://dx.doi.org/10.1182/blood.2020005125.

Der volle Inhalt der Quelle

Annotation:

Abstract Newly diagnosed multiple myeloma (NDMM) patients treated with immunomodulatory drugs are at high risk of venous thromboembolism (VTE), but data are lacking from large prospective cohorts. We present thrombosis outcome data from Myeloma IX (n = 1936) and Myeloma XI (n = 4358) phase 3 randomized controlled trials for NDMM that treated transplant-eligible and transplant-ineligible patients before and after publication of thrombosis prevention guidelines. In Myeloma IX, transplant-eligible patients randomly assigned to cyclophosphamide, vincristine, doxorubicin, and dexamethasone (CVAD) i

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Mellish, Martha, Kasadee Allan, and Bronwyn Crane. "Effects of sunlight hours and hormones on double ovulation, and singleton and twin pregnancies in mares." Clinical Theriogenology 13, no. 2 (2021): 81–84. http://dx.doi.org/10.58292/ct.v13.9356.

Der volle Inhalt der Quelle

Annotation:

Equine twin pregnancies are almost exclusively dizygotic, without the application of advanced reproductive technologies, requiring 2ovulations in 1 estrous cycle. Breeding records were used to determine the effects of sunlight hours, prostaglandin F2α, human chorionicgonadotropin, deslorelin (a gonadotropin releasing hormone agonist), and progesterone and estradiol on double ovulation rates,and singleton and twin pregnancy rates. Breeding records of mares (n = 267) and their estrous cycles (n = 914) were analysed. Doubleovulations occurred in 10.5% (96/914) of estrous cycles. Twin pregnancies

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Tsuchiya, Norihiko, Yoshiaki Yamamoto, Hirotsugu Uemura, et al. "Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 Japanese subgroup analysis." Journal of Clinical Oncology 39, no. 6_suppl (2021): 425. http://dx.doi.org/10.1200/jco.2021.39.6_suppl.425.

Der volle Inhalt der Quelle

Annotation:

425 Background: A randomized phase III trial (JAVELIN Bladder 100; NCT02603432) to investigate avelumab (anti–PD-L1) as 1L maintenance therapy in patients with advanced UC met its primary objective, demonstrating significantly prolonged overall survival (OS) with Ave + BSC vs BSC alone in all randomized patients and in patients with PD-L1+ tumors. We report efficacy and safety in Japanese patients enrolled in this study. Methods: Eligible patients with unresectable locally advanced or metastatic UC that had not progressed with 4-6 cycles of gemcitabine with either cisplatin or carboplatin were

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Schulz, Victor C., Pedro S. C. de Magalhaes, Camila C. Carneiro, et al. "Improved Outcomes after Reperfusion Therapies for Ischemic Stroke: A “Real-world” Study in a Developing Country." Current Neurovascular Research 17, no. 4 (2020): 361–75. http://dx.doi.org/10.2174/1567202617666200521083132.

Der volle Inhalt der Quelle

Annotation:

Background: It is unknown if improvements in ischemic stroke (IS) outcomes reported after cerebral reperfusion therapies (CRT) in developed countries are also applicable to the “real world” scenario of low and middle-income countries. We aimed to measure the long-term outcomes of severe IS treated or not with CRT in Brazil. Methods: Patients from a stroke center of a state-run hospital were included. We compared the survival probability and functional status at 3 and 12 months in patients with severe IS treated or not with CRT. From 2010 to 2011, we performed intravenous reperfusion when patie

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Jin, Linda, Bradley Krasnick, Jesse Davidson, et al. "The effect of postoperative morbidity on long-term survival after curative resection for extra-hepatic biliary tumors: A multi-institution analysis from the U.S. Extrahepatic Biliary Malignancy Consortium." Journal of Clinical Oncology 34, no. 4_suppl (2016): 435. http://dx.doi.org/10.1200/jco.2016.34.4_suppl.435.

Der volle Inhalt der Quelle

Annotation:

435 Background: Surgical resection is the cornerstone of curative therapy for extrahepatic biliary tumors (EHBTs) Postoperative complications (POCs) can negatively impact survival after oncologic resection. We evaluated the impact of POCs on survival after resection of EHBTs. Methods: We analyzed 914 patients from ten institutions of the U.S. Extrahepatic Biliary Malignancy Consortium who underwent curative resection for gallbladder adenocarcinoma (n=389), hilar (n=295) and distal (n=294) cholangiocarcinoma between 1998 and 2015. POCs were graded using the modified Clavien-Dindo system. Overal

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

Patel, Kiran, Brenda Diergaarde, Adam Brufsky, et al. "Incidence of febrile neutropenia with use of docetaxel plus cyclophosphamide (TC) for breast cancer." Journal of Clinical Oncology 35, no. 15_suppl (2017): e12073-e12073. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e12073.

Der volle Inhalt der Quelle

Annotation:

e12073 Background: Incidence of febrile neutropenia (FN) is reported as 5% in breast cancer patients receiving TC (Jones et al., JCO 2006), which would not justify the usage of prophylactic granulocyte colony stimulating factors (G-CSF). We previously showed that the incidence of FN may be as high as 23% in a small study. (N = 130, Soni et al., ASCO 2011). In the current study, we determined the incidence of FN in a larger cohort (N = 415), and evaluated the usage of G-CSF and its relation to FN, age, stage, and hormonal status. Methods: We retrospectively reviewed the electronic medical recor

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Bando, H., T. Yoshino, E. Shinozaki, et al. "Clinical outcome in patients with metastatic colorectal cancer harboring KRAS p.G13D mutation treated with cetuximab." Journal of Clinical Oncology 29, no. 4_suppl (2011): 448. http://dx.doi.org/10.1200/jco.2011.29.4_suppl.448.

Der volle Inhalt der Quelle

Annotation:

448 Background: Metastatic colorectal cancer patients with KRAS codon 12 or 13 mutated tumors are presently excluded from treatment with cetuximab (Cmab). On the other hand, a few patients who have mutated KRAS status occasionally respond to Cmab. The tumors of those patients predominantly had codon 13 mutation, and all codon 13 responder have mutation of p.G13D. We now compared the efficacy of Cmab among patients with p.G13D- mutant, other KRAS mutant and KRAS wild-type colorectal cancer. Methods: The patients from 9 Japanese institutions were retrospectively collected and analyzed. All patie

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Mehr Quellen

Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!